Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease

Journal of the American Society of Nephrology

Volumn 27, Issue 6, 2016, Pages 1861-1868

  Hwang, Young Hwan ^a,b   Conklin, John ^b   Chan, Winnie ^b   Roslin, Nicole M ^c   Liu, Jannel ^b   He, Ning ^b   Wang, Kairong ^b   Sundsbak, Jamie L ^d   Heyer, Christina M ^d   Haider, Masoom ^b   Paterson, Andrew D ^c   Harris, Peter C ^d   Pei, York ^b  

^a Eulji General Hospital   (South Korea)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; POLYCYSTIN 1; POLYCYSTIN 2;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEATH; END STAGE RENAL DISEASE; FEMALE; GENE LOCUS; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; INDEL MUTATION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; GENETIC ASSOCIATION STUDY; GENETICS; KIDNEY; MUTATION; PATHOPHYSIOLOGY; PEDIGREE; PROCEDURES;

ADULT; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; KIDNEY; MALE; MUTATION; PEDIGREE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES;

EID: 84992461943     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015060648     Document Type: Article

References (31)

1. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Aresté N, de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT; ERA-EDTA Registry; EuroCYST Consortium; WGIKD: Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: Prevalence and survival-an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 29 [Suppl 4]: iv15-iv25, 2014
2. Harris PC, Rossetti S: Molecular diagnostics for autosomal dominant polycystic kidney disease. Nat Rev Nephrol 6: 197-206, 2010
3. Peters DJ, Sandkuijl LA: Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 97: 128-139, 1992
4. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y: Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 20: 1833-1838, 2009
5. Hateboer N, v Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, BreuningM, Ravine D: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103-107, 1999
6. Dicks E, Ravani P, Langman D, DavidsonWS, Pei Y, Parfrey PS: Incident renal events and risk factors in autosomal dominant polycystic kidney disease: A population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 1: 710-717, 2006
7. Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, Dicks E, Parfrey P, Torra R, San-Millan JL,Coto E, Van DijkM, BreuningM, Peters D, Bogdanova N, Ligabue G, Albertazzi A, Hateboer N, Demetriou K, Pierides A, Deltas C, St George-Hyslop P, Ravine D, Pei Y: Genotyperenal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 14: 1164-1174, 2003
8. Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, Guay-Woodford LM, King BF, Wetzel LH, Baumgarten DA, Kenney PJ, Consugar M, Klahr S, Bennett WM, Meyers CM, Zhang QJ, Thompson PA, Zhu F, Miller JP: Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 17: 3013-3019, 2006
9. Persu A, Duyme M, Pirson Y, Lens XM,Messiaen T, BreuningMH, Chauveau D, LevyM, Grünfeld JP, Devuyst O: Comparison between siblings and twins supports a role formodifiergenes inADPKD.Kidney Int 66: 2132-2136, 2004
10. Paterson AD,Magistroni R, He N,Wang K, Johnson A, Fain PR, Dicks E, Parfrey P, StGeorge-Hyslop P, Pei Y: Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J AmSoc Nephrol 16: 755-762, 2005
11. Fain PR,McFann KK, TaylorMR, TisonM, Johnson AM, Reed B, Schrier RW:Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int 67: 1256-1267, 2005
12. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM, Meyers CM, Walker DL, Bae K, Zhang QJ, Thompson PA, Miller JP, Harris PC; CRISP Consortium: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 18: 2143-2160, 2007
13. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Torres VE, Harris PC: Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 75: 848-855, 2009
14. Pei Y, Lan Z, Wang KR, Garcia-Gonzalez M, He N, Dicks E, Parfrey P, Germino G, Watnick T: A missense mutation in PKD1 attenuates the severity of renal disease. Kidney Int 81: 412-417, 2012
15. Cornec-Le Gall E, Audrézet M-P, Chen JM, Hourmant M, Morin MP, Perrichot R, Charasse C,Whebe B, Renaudineau E, Jousset P, Guillodo MP, Grall-Jezequel A, Saliou P, Férec C, Le Meur Y: Type of PKD1 mutation influences renal outcome in ADPKD. J AmSoc Nephrol 24: 1006-1013, 2013
16. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC: Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. J Clin Invest 122: 4257-4273, 2012
17. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr., Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354: 2122-2130, 2006
18. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249, 2010
19. Ng PC, Henikoff S: Predicting deleterious amino acid substitutions. Genome Res 11: 863-874, 2001
20. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP: Predicting the functional effect of amino acid substitutions and indels. PLoS One 7: e46688, 2012
21. Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, Germino GG, Parfrey P, Somlo S, St George-Hyslop P: Bilineal disease and transheterozygotes in autosomal dominant polycystic kidney disease. Am J Hum Genet 68: 355-363, 2001
22. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, GranthamJJ,Mrug M, HoganMC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators: Imaging classification of autosomal dominant polycystic kidney disease: A simplemodel for selecting patients for clinical trials. J Am Soc Nephrol 26: 160-172, 2015
23. Youssoufian H, Pyeritz RE: Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 3: 748-758, 2002
24. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012
25. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479-486, 2012
26. Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW,Ward CJ,Winearls CG, Torres VE, Harris PC: Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol 23: 915-933, 2012
27. Bergmann C, von Bothmer J, Ortiz Brüchle N, Venghaus A, Frank V, Fehrenbach H, Hampel T, Pape L, Buske A, Jonsson J, Sarioglu N, Santos A, Ferreira JC, Becker JU, Cremer R, Hoefele J, BenzMR,Weber LT, Buettner R, Zerres K: Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol 22: 2047-2056, 2011
28. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, SanMillan JL, Gibson R, Breuning M, Peters D, Ravine D: Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 20: 205-212, 2009
29. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C: Human Splicing Finder: An online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37: e67, 2009
30. Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LJ, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC; CRISP Consortium: Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int 74: 1468-1479, 2008
31. Rondeau V, Mazroui Y, Gonzalez J: Frailtypack: An R package for analysis of correlated survival data with Frailty models using penalized likelihood estimation or parametrical estimation. J Stat Softw 47: 1-28, 2012